Syremis Therapeutics raises $165M in Series A to advance novel mental health treatments
Syremis Therapeutics, a clinical-stage biopharmaceutical company, has secured $165 million in a Series A funding round led by Dexcel Pharma. The round also included investments from Third Rock Ventures, Bain Capital Life Sciences, GV (Google Ventures), QVT, and Pictet, underscoring strong investor confidence in the company’s mission and pipeline.
Syremis Therapeutics is developing innovative medicines targeting mental health disorders, with a focus on schizophrenia and other neuropsychiatric conditions. Founded by Elisabeth Kogan and Elena Kagan—two female executives—and Menashe Levy, the company operates out of Tel Aviv, Israel, and Boston, Massachusetts. The founders bring a strong scientific and leadership background to address critical unmet needs in mental health treatment.
Deal Details
Amount: $165 million
Round: Series A
Investors: Dexcel Pharma, Third Rock Ventures, Bain Capital Life Sciences, GV (Google Ventures), QVT, Pictet
Location: Tel Aviv, Israel and Boston, Massachusetts, USA
About Syremis Therapeutics
Syremis Therapeutics is a clinical-stage biopharmaceutical company focused on developing best-in-class medicines for mental health disorders, including schizophrenia and other neuropsychiatric diseases. The company leverages cutting-edge science to create novel therapeutic candidates aimed at improving patient outcomes in a field with significant unmet medical needs. With a dual presence in Tel Aviv and Boston, Syremis combines global expertise and resources to accelerate drug development. The leadership team, including female co-founders Elisabeth Kogan and Elena Kagan, exemplifies diversity in biotech entrepreneurship and scientific innovation.
What This Means
This substantial Series A financing positions Syremis Therapeutics to advance its clinical programs and expand its research capabilities in the growing mental health biopharmaceutical sector. Mental health disorders remain a major global health challenge, and investment in novel treatments reflects increasing recognition of this need. The involvement of top-tier investors signals strong market confidence in Syremis’s approach and potential to deliver impactful therapies. The funding will support clinical development and help bring new treatment options to patients suffering from complex neuropsychiatric conditions.